34,368 Shares in Prestige Consumer Healthcare Inc. $PBH Bought by Moran Wealth Management LLC

Moran Wealth Management LLC bought a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 34,368 shares of the company’s stock, valued at approximately $2,037,000. Moran Wealth Management LLC owned 0.07% of Prestige Consumer Healthcare at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PBH. UMB Bank n.a. boosted its holdings in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after acquiring an additional 219 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in Prestige Consumer Healthcare during the 4th quarter valued at approximately $29,000. Barrow Hanley Mewhinney & Strauss LLC raised its holdings in Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after purchasing an additional 283 shares during the last quarter. Geneos Wealth Management Inc. raised its holdings in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the last quarter. Finally, Torren Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insiders Place Their Bets

In other news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the transaction, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PBH. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Finally, Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $49.38 on Monday. The firm has a 50 day moving average of $49.36 and a 200-day moving average of $58.25. The company has a market cap of $2.34 billion, a price-to-earnings ratio of 12.63, a price-to-earnings-growth ratio of 1.59 and a beta of 0.35. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare Inc. has a 52 week low of $42.62 and a 52 week high of $80.69.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The company had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm’s revenue was down 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).